Stock IBT B INFANT BACTERIAL THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Infant Bacterial Therapeutics AB

Equities

IBT B

SE0008015259

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:44 2024-05-22 am EDT 		5-day change 1st Jan Change
96 SEK +3.00% Intraday chart for Infant Bacterial Therapeutics AB -1.84% +6.67%
May. 07 Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Feb. 08 Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Annual General Meeting of Infant Bacterial Therapeutics
AQ
Infant Bacterial Therapeutics () : Interim report January 1 - March 31, 2024
PU
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – March 31, 2024
AQ
Infant Bacterial Therapeutics : Major Milestone Achieved - Last Patient Enrolled in Infant Bacterial Therapeutics' Phase 3 Study
PU
Major Milestone Achieved - Last Patient Enrolled in Infant Bacterial Therapeutics’ Phase 3 Study
AQ
Notice of Annual General Meeting of Infant Bacterial Therapeutics
AQ
Infant Bacterial Therapeutics AB publishes the Annual Report for 2023
AQ
Infant Bacterial Therapeutics AB (publ), Interim report January 1-December 31, 2023
AQ
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2023
AQ
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2024
AQ
Infant Bacterial Therapeutics AB (publ) Interim report January 1 - June 30, 2023
GL
New number of shares and votes in IBT
GL
New number of shares and votes in IBT
AQ
Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation
AQ
IBT announces outcome of its rights issue
GL
Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation 
GL
The futility analysis for IBT’s Connection Study positive
GL
The futility analysis for IBT’s Connection Study positive
AQ
IBT continues to recruit prematurely born infants to The Connection Study following a planned safety analysis.
GL
New patent for Infant Bacterial Therapeutics has been approved in Europe
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IBT B Stock
  4. News Infant Bacterial Therapeutics AB
  5. Press Releases